CoGyn Pharmaceuticals, Inc. completed the acquisition of MATRX Pharmaceuticals S.A. in a reverse merger transaction.
On November 2, 2015, at the shareholder meeting of SPAC I S.A., the shareholders approved name change to CoGyn Pharmaceuticals SA and chose new supervisory Board. Robert Cohen will be appointed and will serve as new Chairman of management Board. The deal is expected to close in few weeks.
On December 4, 2015, SPAC I S.A. registers name change to CoGyn Pharmaceuticals SA.
CoGyn Pharmaceuticals pledged to pay an advance payment of PLN 10 million for acquisition of CoGyn Pharmaceuticals Inc. shares. Payment was conducted as deduction of investor's liabilities towards CoGyn Pharmaceuticals Inc. As a result, CoGyn Pharmaceuticals Inc. will become CoGyn Pharmaceuticals SA unit and will be listed on Warsaw Stock Exchange.
On February 16, 2016, CoGyn Pharmaceuticals SA resolves to change name to MATRX Pharmaceuticals SA.
CoGyn Pharmaceuticals, Inc. completed the acquisition of MATRX Pharmaceuticals S.A. (WSE:SP1) in a reverse merger transaction on March 11, 2016.